Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer

- Avery-Kiejda, Kelly A., Braye, Stephen G., Mathe, Andrea, Forbes, John F., Scott, Rodney J.

The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer

- Avery-Kiejda, Kelly A., Braye, Stephen G., Forbes, John F., Scott, Rodney J.

HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

- Bartlett, John M. S., Ahmed, Ikhlaaq, Brookes, Cassandra L., Forbes, John F., Viale, Giuseppe, Cuzick, Jack, Dowsett, Mitchell, Rea, Daniel W., Regan, Meredith M., Sestak, Ivana, Mallon, Elizabeth A., Dell'Orto, Patrizia, Thürlimann, Beat, Seynaeve, Caroline, Putter, Hein, Van de Velde, Cornelis J. H.

Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study

- Bliss, Judith M., Kilburn, Lucy S., van de Velde, Cornelius J. H., Lønning, Per. E., Morden, James, Reise, Justine, Cisar, Laura, Menschik, Thomas, Coombes, R. Charles, Coleman, Robert E., Forbes, John F., Coates, Alan S., Jones, Stephen E., Jassem, Jack, Delozier, Thierry, Andersen, Jørn, Paridaens, Robert

Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence

- Chirgwin, Jacquie H., Giobbie-Hurder, Anita, Forbes, John F., Neven, Patrick, Láng, István, Colleoni, Marco, Thürlimann, Beat, Coates, Alan S., Price, Karen N., Ejlertsen, Bent, Debled, Marc, Gelber, Richard D., Goldhirsch, Aron, Smith, Ian, Rabaglio, Manuela

Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015

- Coates, A. S., Winer, E. P., Bergh, Jonas, Bonnefoi, Hervé, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Ejlertsen, Bent, Goldhirsch, A., Forbes, John F., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, Fabrice, Baselga, José

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study

- Colleoni, Marco, Giobbie-Hurder, Anita, Chirgwin, Jacquie, Pienkowski, Tadeusz, Wardley, Andrew, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Regan, Meredith M., Thürlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert, Láng, István, Smith, Ian

Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V

- Colleoni, Marco, Sun, Zhuoxin, Goldhirsch, Aron, Price, Karen N., Karlsson, Per, Forbes, John F., Thürlimann, Beat, Gianni, Lorenzo, Castiglione, Monica, Gelber, Richard D., Coates, Alan S.

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial

- Crivellari, Diana, Sun, Zhuoxin, Gelber, Richard D., Colleoni, Marco, Lang, Istvan, Del Mastro, Lucia, Gladieff, Laurence, Rabaglio, Manuela, Smith, Ian E., Chirgwin, Jacquie H., Goldhirsch, Aron, Coates, Alan S., Price, Karen N., Thurlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert J., Castiglione-Gertsch, Monica

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

- Cuzick, Jack, Sestak, Ivana, Bonanni, Bernardo, Palva, Tina, Howell, Anthony, Forbes, John F., Dowsett, Mitch, Knox, Jill, Cawthorn, Simon, Saunders, Christobel, Roche, Nicola, Mansel, Robert E., von Minckwitz, Gunter

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

- Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F.

Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study

- Cuzick, Jack, Warwick, Jane, Pinney, Elizabeth, Duffy, Stephen W., Cawthorn, Simon, Howell, Anthony, Forbes, John F., Warren, Ruth M. L.

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

- Cuzick, Jack, Sestak, Ivana, Cawthorn, Simon, Hamed, Hisham, Holli, Kaija, Howell, Anthony, Forbes, John F.

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial

- Cuzick, Jack, Sestak, Ivana, Forbes, John F., Dowsett, Mitch, Cawthorn, Simon, Mansel, Robert E., Loibl, Sibylle, Bonanni, Bernardo, Evans, D. Gareth, Howell, Anthony

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of randomised controlled trial

- Cuzick, Jack, Sestak, Ivanka, Forbes, John F., Dowsett, Mitch, Cawthorn, Simon, Mansel, Robert E., Loibl, Sibylle, Bonanni, Bernardo, Evans, D. Gareth, Howell, Anthony

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

- Cuzick, Jack, Sestak, Ivana, Pinder, Sarah E., Ellis, Ian O., Forsyth, Sharon, Bundred, Nigel J., Forbes, John F., Bishop, Hugh, Fentiman, Ian S., George, William D.

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer

- Cuzick, Jack, Dowsett, Mitch, Howell, Anthony, Buzdar, Aman U., Forbes, John F., Pineda, Silvia, Wale, Christopher, Salter, Janine, Quinn, Emma, Zabaglo, Lila, Mallon, Elizabeth, Green, Andrew R., Ellis, Ian O.

Preventive therapy for breast cancer: a consensus statement

- Cuzick, Jack, DeCensi, Andrea, Vogel, Victor, Zwierzina, Heinz, Arun, Banu, Brown, Powell H., Castiglione, Monica, Dunn, Barbara, Forbes, John F., Glaus, Agnes, Howell, Anthony, Von Minckwitz , Gunter

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

- Cuzick, Jack, Sestak, Ivana, Mershon, John, Mitlak, Bruce H., Powles, Trevor, Veronesi, Umberto, Vogel, Victor, Wickerham, D. Lawrence, Bonanni, Bernardo, Costantino, Joseph P., Cummings, Steve, DeCensi, Andrea, Dowsett, Mitch, Forbes, John F., Ford, Leslie, LaCroix, Andrea Z.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

- Davies, Christina, Pan, Hongchao, Bradbury, Joan, Clarke, Michael, Collins, Rory, Davis, Susan R., Delmestri, Antonella, Forbes, John F., Haddad, Peiman, Hou, Ming-Feng, Inbar, Moshe, Khaled, Hussein, Godwin, Jon, Kielanowska, Joanna, Kwan, Wing-Hong, Mathew, Beela S., Mittra, Indraneel, Mueller, Bettina, Nicolucci, Antonio, Peralta, Octavio, Pernas, Fany, Petruzelka, Lubos, Pienkowski, Tadeusz, Gray, Richard, Radhika, Ramachandran, Rajan, Balakrishnan, Rubach, Maryan T., Tort, Sera, Urrutia, Gerard, Valentini, Miriam, Wang, Yaochen, Peto, Richard, Arriagada, Rodrigo, Raina, Vinod, Abraham, Mirta, Medeiros Alencar, Victor Hugo, Badran, Atef, Bonfill, Xavier